Valuation: AC Immune SA

Market Cap 182M 222M 195M 167M 313M 21.41B 318M 2.16B 842M 10.52B 834M 816M 36.39B P/E 2026 *
-6.26x
P/E 2027 * 10.1x
Enterprise Value 137M 167M 147M 125M 236M 16.12B 239M 1.62B 634M 7.93B 629M 615M 27.41B EV / Sales 2026 *
3.77x
EV / Sales 2027 * 2.26x
Free-Float
56.09%
Yield 2026 *
-
Yield 2027 * -
1 day-0.89%
1 week+0.23%
Current month-7.35%
1 month-13.19%
3 months-22.36%
6 months-36.64%
Current year-29.78%
1 week 2.16
Extreme 2.16
2.34
1 month 2.12
Extreme 2.12
2.66
Current year 2.1
Extreme 2.095
3.9
1 year 2.03
Extreme 2.03
4
3 years 1.43
Extreme 1.4299
5.14
5 years 1.43
Extreme 1.4299
12.61
10 years 1.43
Extreme 1.4299
19.97
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-10
Director of Finance/CFO 37 2021-12-31
Chief Tech/Sci/R&D Officer 45 2012-12-31
Director TitleAgeSince
Director/Board Member 70 2018-12-31
Director/Board Member 72 2020-11-19
Director/Board Member 65 2021-10-28
Date Insider Type Main position Quantity % Market Cap.
6/11/26 Free

Director

59,418 0.0584%
6/11/26 Free

Director

55,457 0.0545%
6/11/26 Free

Director

55,457 0.0545%
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%+0.23%-9.26%-25.76% 222M
+1.14%-2.49%+16.85%-9.26% 66.32B
+1.23%+2.80%+37.51%+202.14% 52.6B
+10.08%+51.80%+51.80%+51.80% 43.27B
-1.32%-6.34%-56.98%-57.24% 38.64B
+1.00%-1.67%+52.76%-26.88% 29.62B
+0.98%+0.37%+66.95%+85.45% 23.31B
-4.30%-12.29%+59.42%-55.92% 22.62B
-1.21%-4.51%+2.22%+174.24% 20.22B
-0.22%-0.95%+61.97%+123.78% 16.29B
Average +0.64%-0.92%+28.32%+46.23% 31.31B
Weighted average by Cap. +1.43%-0.65%+27.63%+49.54%

Financials

2026 *2027 *
Net sales 36.27M 44.4M 39M 33.28M 62.53M 4.28B 63.5M 431M 168M 2.1B 167M 163M 7.27B 87.76M 107M 94.36M 80.53M 151M 10.35B 154M 1.04B 407M 5.09B 403M 395M 17.59B
Net income -30.36M -37.16M -32.64M -27.86M -52.34M -3.58B -53.14M -360M -141M -1.76B -140M -137M -6.08B 17.54M 21.47M 18.86M 16.09M 30.24M 2.07B 30.71M 208M 81.37M 1.02B 80.61M 78.87M 3.52B
Net Debt -44.8M -54.85M -48.17M -41.11M -77.24M -5.28B -78.43M -532M -208M -2.6B -206M -201M -8.98B 17.1M 20.94M 18.39M 15.69M 29.48M 2.02B 29.94M 203M 79.33M 991M 78.59M 76.9M 3.43B
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
106
Date Price Change Volume
26-07-24 US$2.210 -1.34% 333,796
26-07-23 US$2.240 -1.32% 79,276
26-07-22 US$2.270 -1.30% 245,506
26-07-21 US$2.300 +2.22% 94,875
26-07-20 US$2.250 +2.27% 206,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.830CHF
Average target price
6.956CHF
Spread / Average Target
+280.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACIU Stock